F Guo1, X Song1, Y Li1, W Guan2, W Pan1, W Yu2, T Li3,4, E Hsieh5,6. 1. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan, Wangfujing Street, Beijing, 100730, China. 2. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. 3. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan, Wangfujing Street, Beijing, 100730, China. litsh@263.net. 4. Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. litsh@263.net. 5. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan, Wangfujing Street, Beijing, 100730, China. evelyn.hsieh@yale.edu. 6. Section of Rheumatology, Allergy, and Clinical Immunology, Yale School of Medicine, 300 Cedar Street, TAC S-525, PO Box 208031, New Haven, CT, 06517, USA. evelyn.hsieh@yale.edu.
Abstract
This is the first study to report changes in BMD and related risk factors among Chinese patients with HIV after initiation of tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy. Greater bone mineral density (BMD) loss was observed in patients treated with TDF, compared to those on non-TDF-containing regimens. Our findings provide important knowledge regarding the risk factors in the long-term clinical management of patients with HIV in China. INTRODUCTION: Persons living with HIV (PLWH) are at increased risk for osteoporosis and fracture. Tenofovir disoproxil fumarate (TDF) has been associated with higher rates of bone mineral density (BMD) loss, osteoporosis, and fracture. Few studies have studied the impact among PLWH in Asia. METHODS: We analyzed retrospectively patients from the outpatient HIV clinic of a large tertiary hospital in Beijing, China, from March 2007 to May 2016. Patients who had dual-energy X-ray absorptiometry testing prior to antiretroviral initiation and at 48 and/or 96 weeks after initiation were included in this analysis. RESULTS: A total of 136 patients were included (mean age 36.0 ± 10.6 years) and over 90% participants were male and Han Chinese ethnicity. We observed greater declines in BMD at the spine from baseline to week 48 (-2.94% vs. -0.74%) and at the hip from baseline to week 96 (-4.37% vs. -2.34%) in the TDF group compared with the non-TDF group. With regard to HIV-specific parameters, longer duration since HIV diagnosis and undetectable viral load over time were associated with lower BMD at the hip [relative risk (RR) 0.97, 95% confidence index (CI) (0.95, 0.99) per 1 year increase and RR 0.96, 95%CI (0.94, 0.99), respectively] and femoral neck [RR 0.97, 95%CI (0.95, 0.99) per 1 year increase and RR 0.97, 95%CI (0.95, 0.998), respectively] over 96 weeks. CONCLUSIONS: This is the first study to report changes in BMD among PLWH after initiation of TDF-based antiretroviral therapy in China. Our findings provide important knowledge for the long-term clinical management of PLWH from this region.
This is the first study to report changes in BMD and related risk factors among Chinese patients with HIV after initiation of tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy. Greater bone mineral density (BMD) loss was observed in patients treated with TDF, compared to those on non-TDF-containing regimens. Our findings provide important knowledge regarding the risk factors in the long-term clinical management of patients with HIV in China. INTRODUCTION: Persons living with HIV (PLWH) are at increased risk for osteoporosis and fracture. Tenofovir disoproxil fumarate (TDF) has been associated with higher rates of bone mineral density (BMD) loss, osteoporosis, and fracture. Few studies have studied the impact among PLWH in Asia. METHODS: We analyzed retrospectively patients from the outpatient HIV clinic of a large tertiary hospital in Beijing, China, from March 2007 to May 2016. Patients who had dual-energy X-ray absorptiometry testing prior to antiretroviral initiation and at 48 and/or 96 weeks after initiation were included in this analysis. RESULTS: A total of 136 patients were included (mean age 36.0 ± 10.6 years) and over 90% participants were male and Han Chinese ethnicity. We observed greater declines in BMD at the spine from baseline to week 48 (-2.94% vs. -0.74%) and at the hip from baseline to week 96 (-4.37% vs. -2.34%) in the TDF group compared with the non-TDF group. With regard to HIV-specific parameters, longer duration since HIV diagnosis and undetectable viral load over time were associated with lower BMD at the hip [relative risk (RR) 0.97, 95% confidence index (CI) (0.95, 0.99) per 1 year increase and RR 0.96, 95%CI (0.94, 0.99), respectively] and femoral neck [RR 0.97, 95%CI (0.95, 0.99) per 1 year increase and RR 0.97, 95%CI (0.95, 0.998), respectively] over 96 weeks. CONCLUSIONS: This is the first study to report changes in BMD among PLWH after initiation of TDF-based antiretroviral therapy in China. Our findings provide important knowledge for the long-term clinical management of PLWH from this region.
Entities:
Keywords:
Bone mineral density; Fracture; Human immunodeficiency virus; Protease inhibitors; Tenofovir disoproxil fumarate
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Jennifer F Hoy; Robyn Richardson; Peter R Ebeling; Jhon Rojas; Nicholas Pocock; Stephen J Kerr; Esteban Martinez; Andrew Carr Journal: AIDS Date: 2018-09-10 Impact factor: 4.177
Authors: Todd T Brown; Jennifer Hoy; Marco Borderi; Giovanni Guaraldi; Boris Renjifo; Fabio Vescini; Michael T Yin; William G Powderly Journal: Clin Infect Dis Date: 2015-01-21 Impact factor: 9.079
Authors: E Biver; A Calmy; B Aubry-Rozier; M Birkhäuser; H A Bischoff-Ferrari; S Ferrari; D Frey; R W Kressig; O Lamy; K Lippuner; N Suhm; C Meier Journal: Osteoporos Int Date: 2019-01-02 Impact factor: 4.507
Authors: Paul E Sax; Andrew Zolopa; Indira Brar; Richard Elion; Roberto Ortiz; Frank Post; Hui Wang; Christian Callebaut; Hal Martin; Marshall W Fordyce; Scott McCallister Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Anda Gonciulea; Ruibin Wang; Keri N Althoff; Frank J Palella; Jordan Lake; Lawrence A Kingsley; Todd T Brown Journal: AIDS Date: 2017-06-19 Impact factor: 4.177
Authors: Miguel Cervero; Rafael Torres; Jose Luís Agud; Victoria Alcázar; Juan José Jusdado; Concepción García-Lacalle; Santiago Moreno Journal: PLoS One Date: 2018-04-30 Impact factor: 3.240
Authors: Julie A Womack; Terrence E Murphy; Christine Ramsey; Harini Bathulapalli; Linda Leo-Summers; Alexandria C Smith; Jonathan Bates; Samah Jarad; Thomas M Gill; Evelyn Hsieh; Maria C Rodriguez-Barradas; Phyllis C Tien; Michael T Yin; Cynthia Brandt; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2021-10-01 Impact factor: 3.771